Skip to main content
SpringerLink
Log in

Austrian Joint ÖGGH-ÖGIR-ÖGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma

Gemeinsames österreichisches ÖGGH-ÖGIR-ÖGHO-ASSO Positionspapier zum Einsatz der transarteriellen Chemoembolisation (TACE) beim Hepatozellulären Karzinom

  • Consensus report
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

Zusammenfassung

Die transarterielle Chemoembolisation (TACE) bei hepatozellulärem Karzinom (HCC) ist eine der meistverwendeten Standardtechniken zur Behandlung dieser Erkrankung. Die Rolle der TACE ist relativ gut definiert für den am meisten verwendeten Behandlungsalgorithmus, den "Barcelona Clinic Liver Cancer (BCLC) Staging System and Treatment" Algorithmus. Aber kein allgemeiner Behandlungsalgorithmus geht auf die technischen Details des Eingriffs ein und zudem gibt es immer einige Patienten, welche nicht genau in die von BCLC oder einem anderen Behandlungsschema vordefinierten Gruppen passen. Ausserdem werden Indikationen und Kontraindikationen manchmal von den unterschiedlichen Fachdisziplinen, welche in das Management dieser Patienten involviert sind, unterschiedlich gesehen. Wir präsentieren hier das gemeinsame Experten-Positionspapier der Österreichischen Gesellschaften für Gastroenterologie und Hepatologie (ÖGGH), Interventionelle Radiologie (ÖGIR), Hämatologie und Onkologie (ÖGHO) und Chirurgische Onkologie (ASSO) bezüglich der technischen Aspekte, der Indikationen und der Kontraindikationen für den Einsatz der TACE im Management des HCC.

Summary

Transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) is one of the most frequently applied standard treatments for this disease. The role for TACE is fairly well defined within the most widely used treatment algorithm for HCC, die Barcelona Clinic Liver Cancer (BCLC) staging system and treatment algorithm. But no general treatment algorithm will go into the technical details of any procedure and several patients will not fit ideally into the patient groups predefined in BCLC or any other treatment algorithm. Furthermore, indications and contraindications sometimes are viewed differently by the various medical specialties involved in taking care of such patients. We present here the joint expert position statement of the Austrian Societies of Gastroenterology and Hepatology (ÖGGH), Interventional Radiology (ÖGIR), Hematology and Oncology (ÖGHO), and Surgical Oncology (ASSO) on the technical aspects, indications, and contraindication for the use of TACE in the management of HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762–73

    Article  PubMed  CAS  Google Scholar 

  • Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011;53:1020–2

    Article  PubMed  Google Scholar 

  • Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907–17

    Article  PubMed  Google Scholar 

  • Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, et al. Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes. Gastroenterology 2010;138:52

    Article  PubMed  CAS  Google Scholar 

  • Jelic S, Sotiropoulos GC. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v59–64

    Article  PubMed  Google Scholar 

  • Brown DB, Cardella JF, Sacks D, Goldberg SN, Gervais DA, Rajan DK, Vedantham S, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2009;20:S219–S226, S226 e211–210

    Article  PubMed  Google Scholar 

  • Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011;37:212–20

    Article  PubMed  Google Scholar 

  • Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164–71

    Article  PubMed  CAS  Google Scholar 

  • Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734–9

    Article  PubMed  Google Scholar 

  • Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6–25

    Article  PubMed  Google Scholar 

  • Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, Makuuchi M. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol 2010;194:830–7

    Article  PubMed  Google Scholar 

  • Kwok PC, Lam TW, Chan SC, Chung CP, Wong WK, Chan MK, Lo HY, et al. A randomized clinical trial comparing autologous blood clot and gelfoam in transarterial chemoembolization for inoperable hepatocellular carcinoma. J Hepatol 2000;32:955–64

    Article  PubMed  CAS  Google Scholar 

  • Brown DB, Pilgram TK, Darcy MD, Fundakowski CE, Lisker-Melman M, Chapman WC, Crippin JS. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 2005;16:1661–6

    Article  PubMed  Google Scholar 

  • Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol 2009;10:425–34

    Article  PubMed  Google Scholar 

  • Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170:783–6

    PubMed  CAS  Google Scholar 

  • Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006;12:2563–7

    Article  PubMed  CAS  Google Scholar 

  • Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474–81

    Article  PubMed  CAS  Google Scholar 

  • Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41–52

    Article  PubMed  Google Scholar 

  • Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010;101:476–80

    PubMed  Google Scholar 

  • Covey AM, Maluccio MA, Brody LA, Sofocleous CT, Getrajdman GI, Brown KT. Re: Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 2006;17:1209; author reply 1209–10

    Article  PubMed  Google Scholar 

  • Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, Moschouris H, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010;33:541–51

    Article  PubMed  Google Scholar 

  • Malagari K, Pomoni M, Spyridopoulos TN, Moschouris H, Kelekis A, Dourakis S, Alexopoulou E, et al. Safety Profile of Sequential Transcatheter Chemoembolization with DC Bead(): Results of 237 Hepatocellular Carcinoma (HCC) Patients. Cardiovasc Intervent Radiol 2010

  • Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, Hasegawa H, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 1987;163:345–51

    PubMed  CAS  Google Scholar 

  • Miyayama S, Yamashiro M, Okuda M, Yoshie Y, Sugimori N, Igarashi S, Nakashima Y, et al. Usefulness of cone-beam computed tomography during ultraselective transcatheter arterial chemoembolization for small hepatocellular carcinomas that cannot be demonstrated on angiography. Cardiovasc Intervent Radiol 2009;32:255–64

    Article  PubMed  Google Scholar 

  • Takayasu K. Chemoembolization for unresectable hepatocellular carcinoma in Japan. Oncology 2010;78 Suppl 1:135–41

    Article  PubMed  Google Scholar 

  • Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011;3:CD004787

    PubMed  Google Scholar 

  • Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429–42

    Article  PubMed  CAS  Google Scholar 

  • Zhou WP, Lai EC, Li AJ, Fu SY, Zhou JP, Pan ZY, Lau WY, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg 2009;249:195–202

    Article  PubMed  Google Scholar 

  • Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, Visa J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996;111:1018–22

    Article  PubMed  CAS  Google Scholar 

  • Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis [see comments]. N Engl J Med 1996;334:693–9

    Article  PubMed  CAS  Google Scholar 

  • Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90

    Article  PubMed  CAS  Google Scholar 

  • Brown DB, Geschwind JF, Soulen MC, Millward SF, Sacks D. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 2009;20:S317–23

    Article  PubMed  Google Scholar 

  • Lencioni R, Llovet JM. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. Semin Liver Dis 2010;30:52–60

    Article  PubMed  CAS  Google Scholar 

  • Dufour JF, Hoppe H, Heim MH, Helbling B, Maurhofer O, Szucs-Farkas Z, Kickuth R, et al. Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study. Oncologist 2010

  • Pinter M, Sieghart W, Reiberger T, Ferlitsch A, Müller C, Peck-Radosavljevic M. An interim safety analysis of sorafenib plus transarterial chemoembolization in hepatocellular carcinoma – a phase I/II pilot study (SORATCAE-1 trial). Hepatology 2010;52 (Suppl. 1):A1759

    Google Scholar 

  • Ulbrich G, Kölblinger C, Pinter M, Reiberger T, Ferlitsch A, Sieghart W, Lammer J, et al. AVATACE-1 trial: Bevacizumab as inhibitor of collateral tumor-vessel-growth during transarterial chemoembolisation (TACE) for Hepatocellular Carcinoma - a double-blind, randomized, placebo-controlled pilot-trial. Hepatology 2010;52 (Suppl. 1):A1763

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung Gastroenterologie & Hepatologie, KIM III, AKH & MedUniWien, Vienna, Austria

    Markus Peck-Radosavljevic, Wolfgang Sieghart, Christian Müller & Maximilian Schöniger-Hekele

  2. Abteilung Kardiovaskuläre und Interventionelle Radiologie, Klinik für Radiodiagnostik, AKH & MedUniWien, Vienna, Austria

    Claus Kölblinger, Christina Plank, Martin Funovics & Johannes Lammer

  3. Zentralröntgen, KA Rudolfstiftung, Vienna, Austria

    Markus Reiter

  4. Abteilung für Transplantation, Universitätsklinik für Chirurgie, AKH & MedUniWien, Vienna, Austria

    Martin Schindl & Rudolf Steininger

  5. 1. Medizinische Abteilung mit Gastroenterologie, Krankenhaus Hitzing, Vienna, Austria

    Gregor Ulbrich

  6. Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Graz, Graz, Austria

    Rudolf Stauber

  7. Institut für diagnostische und interventionelle Radiologie, Krankenhaus der Elisabethinen Linz, Linz, Austria

    Manfred Gschwendtner

  8. Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Innsbruck, Innsbruck, Austria

    Ivo Graziadei

  9. Abteilung für Allgemeinchirurgie, Universitätsklinik für Chirurgie, AKH & MedUniWien, Vienna, Austria

    Thomas Gruenberger

  10. Universitätsklinik für Innere Medizin V, Hämatologie und Onkologie, Medizinische Universität Innsbruck, Innsbruck, Austria

    Günther Gastl

  11. Zentralröntgen, SMZ-Süd, Kaiser Franz Josef Spital, Vienna, Austria

    Franz Karnel

Authors
  1. Markus Peck-Radosavljevic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Sieghart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claus Kölblinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Markus Reiter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martin Schindl
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gregor Ulbrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rudolf Steininger
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christian Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rudolf Stauber
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Maximilian Schöniger-Hekele
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Manfred Gschwendtner
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Christina Plank
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Martin Funovics
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Ivo Graziadei
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Johannes Lammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Thomas Gruenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Günther Gastl
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Franz Karnel
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

the Austrian Association of Gastroenterology,Hepatology (ÖGGH)

the Austrian Society of Interventional Radiology (ÖGIR)

the Austrian Society of Hematology and Oncology (ÖGHO)

the Austrian Society for Surgical Oncology (ASSO)

Corresponding author

Correspondence to Markus Peck-Radosavljevic.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peck-Radosavljevic, M., Sieghart, W., Kölblinger, C. et al. Austrian Joint ÖGGH-ÖGIR-ÖGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. Wien Klin Wochenschr 124, 104–110 (2012). https://doi.org/10.1007/s00508-011-0056-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-011-0056-2

Keywords

Search

Navigation